BioSpace News Archive

Ventus Therapeutics, Inc. announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company’s novel NLRP3 inhibitor programs at the Fourth Inflammasome Therapeutics Summit, held from Nov. 29 to Dec. 1 in Boston.

The research antibodies market is projected to grow at a rate of 5.9% in terms of value, from USD 3.35 Billion in 2019 to reach USD 5.33 Billion by 2030.

The global plasmid DNA manufacturing market size accounted for USD 446.13 million in 2022 and is expected to hold USD 2.156 million by 2030 with a CAGR of 21.7%. from 2022 to 2030

The global Immune thrombocytopenia market is forecasted to grow at a rate of 6.7% from USD 2.18 billion in 2019 to USD 3.68 billion in 2030.

The global regenerative medicine market had a market size of USD 7.34 billion in 2019, and is expected to reach a market size of USD 23.57 billion in 2027, and register a revenue growth rate of 15.6% over the forecast period.

The global Pharmaceutical Excipients Market was valued at USD 6.53 billion in 2019 and is expected to reach USD 10.15 billion by the year 2030, at a CAGR of 5.7%.

According to Nova one advisor, the global Immunohistochemistry market size was estimated at USD 2.75 billion in 2022 and is projected to hit around USD 4.19 billion by 2030, growing at a CAGR of 8.29% during the forecast period 2022 to 2030.

Brain Scientific, a Florida-based applied science technology company, announces a new distribution agreement with Fulcrum to drive sales, and the company further announces the hiring of Kevin Winterfield as vice president of marketing and communications to accelerate Brain Scientific’s strategic growth plan heading into the new year.

The global regulatory affairs outsourcing market size is expected to expand around USD 16.6 billion by 2030 from USD 7.11 billion in 2022 with a CAGR of 10.2% from 2021 to 2030.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on December 1, 2022.